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Background
New therapies are needed to manage the increasing 
incidence, severity, and high rate of recurrence of 
Clostridium diﬃ   cile infection.
Methods
Objective: To assess the ability of monoclonal antibodies 
directed against two toxins of C.diﬃ   cile  to  prevent 
recurrence of disease.
Design:  Randomized, double-blind, placebo-controlled 
study
Setting: 30 medical centers in the United States and Canada
Subjects: 200 subjects with diarrhea and a positive stool 
toxin assay for C.diﬃ   cile being treating with 
metronidazole or vancomycin
Intervention: Antibodies administered together as a single 
infusion, each at a dose of 10 mg per kilogram of body 
weight
Outcomes: Th   e primary outcome was laboratory-
documented recurrence of infection during the 84 days 
after the administration  of monoclonal antibodies or 
placebo.
Results
Among the 200 patients who were enrolled (101 in the 
antibody group and 99 in the placebo group), the rate of 
recurrence  of  C. diﬃ   cile infection was lower among 
patients treated with monoclonal antibodies (7% vs. 25%; 
95% conﬁ  dence interval, 7 to 29; P <0.001). Th  e  absolute 
risk reduction (ARR) was 16%, yielded a number needed 
to treat (NNT) of 5.5. Th  e recurrence rates among 
patients with the epidemic BI/NAP1/027 strain were 8% 
for the antibody group and 32% for the placebo group 
(P = 0.06); among patients with more than one previous 
episode of C. diﬃ   cile infection, recurrence rates were 7% 
and 38%, respectively (P = 0.006). Th   e mean duration of 
the initial hospitalization for inpatients did not diﬀ  er 
signiﬁ  cantly between the antibody and placebo groups 
(9.5 and  9.4 days, respectively). At least one serious 
adverse event was reported by 18 patients in the antibody 
group and by 28 patients in the placebo group (P = 0.09).
Conclusions
Th   e addition of monoclonal antibodies against C. diﬃ   cile
toxins to antibiotic agents signiﬁ  cantly  reduced  the 
recurrence of C. diﬃ   cile infection. (ClinicalTrials.gov 
number, NCT00350298 [ClinicalTrials.gov] .)
Commentary
Infection with Clostridium diﬃ   cile  places a signiﬁ  cant 
burden on healthcare facilities. C. diﬃ   cile  has been 
shown to substantially increase hospital costs, hospital 
length of stay, and contribute to mortality  [1,2]. One of 
the major factors hindering successful treatment of 
C.  diﬃ   cile  -associated disease is the high rate of 
recurrence. Risk factors for recurrence include continued 
antibiotic use, antacid use, and older age  [3]. Anecdotal 
evidence supports the use of several diﬀ  erent modalities, 
such as tapering doses of vancomycin, rifaxamin, and 
fecal transplant. Yet, to date none of these therapies have 
been shown to be eﬀ   ective. Myriad risk factors for 
C.  diﬃ   cile infection coalesce in intensive care units, 
making it a highly relevant condition for intensivists.
Th   e present study sought to evaluate the eﬃ   cacy of an 
infusion of monoclonal antibodies directed towards the 
two principle toxins that emanate from C. diﬃ   cile at 
preventing relapse of infection  [4]. Th  e study was a  © 2010 BioMed Central Ltd
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medical centers in the US and Canada. Th  is study 
enrolled 200 subjects between 2006 and 2008 with 
C.  diﬃ   cile  infection in both inpatient and outpatient 
settings. All subjects were followed up for 84 days. Both 
study groups received antibiotic treatment with either 
metronidazole or vancomycin. Th  e proportion of the 
hypervirulent BI/NAPI strain of C. diﬃ   cile was similar in 
both the treatment and placebo arms. Th   e study results 
revealed a signiﬁ   cant decrease in the relapse rate of 
C.  diﬃ   cile in the treatment arm. Th  e absolute risk 
reduction (ARR) was 18% and the number needed to 
treat (NNT) is 5.5. In those with more than one 
recurrence, the ARR of a recurrence was even greater 
(ARR = 31% and NNT = 3.2). Th   ere was no diﬀ  erence in 
the rates of serious adverse events between the placebo 
and treatment groups. However, the infusion failed to 
impact the severity of the initial episode of C. diﬃ   cile 
infection or length of stay. All recurrences occurred in 
hospitalized subjects.
Th   e study was well conducted and had few limitations. 
One limitation was that the study deﬁ   ned severity of 
C.  diﬃ   cile infection solely in terms of stool counts and 
may have unduly dismissed the beneﬁ  t of the antibodies 
against the initial infection. Utilizing other parameters, 
such as quality of life and ability to tolerate meals, may 
have provided more information concerning the impact 
on the initial episode. Additionally, the exclusion of the 
sickest patients with C. diﬃ   cile may have limited the 
generalizability of the study to acute care settings.
Recurrent C. diﬃ   cile  -associated disease is an important 
problem that not only aﬀ   ects the patient, but places 
others at risk from environmental contamination with 
the bacteria. Th  e monoclonal antibodies studied in this 
paper provide hope that those plagued with recurrent 
infections can be treated eﬀ   ectively and safely. Th  e 
utilization of monoclonal antibodies against infectious 
diseases is a crucial advance in developing speciﬁ  c 
therapies that are targeted at the organism of interest and 
not likely to inﬂ   ict collateral damage to the patient’s 
microbiome, an important point made in the editorial 
accompanying the study  [5].
Recommendation
In conclusion, the addition of monoclonal antibodies did 
not alter the severity of Clostridium diﬃ   cle-associated 
disease. However, monoclonal antibodies will reduce the 
recurrence of disease and should be routinely adminis-
tered to those at highest risk for recurrence. Determining 
the cost-eﬀ   ectiveness of this approach remains to be 
seen.
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